Overview

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Status:
RECRUITING
Trial end date:
2030-03-30
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.
Phase:
PHASE1
Details
Lead Sponsor:
Amgen
Treatments:
abiraterone
darolutamide